Taysha Gene Therapies Issues Stock Grants to Four New Hires
Taysha granted RSUs and stock options to four new employees as hiring incentives under a Nasdaq-approved inducement plan.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Board of Directors' Compensation Committee approved equity awards for four newly hired employees on October 1, 2026, as part of standard inducement compensation tied to their employment agreements.
The awards consist of restricted stock units representing 384,000 shares of Taysha common stock, along with an option to purchase an additional 92,400 shares. Both grants were issued under the company's 2023 Inducement Plan, a mechanism that allows publicly traded companies to offer equity to incoming employees without a shareholder vote, provided the grants comply with Nasdaq Listing Rule 5635(c)(4).
Read more Biogen's Litifilimab Shows Durable CLE Benefits at 52 Weeks →
Dallas-based Taysha is a clinical-stage biotechnology firm developing adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. The company has been expanding its workforce as it advances its CNS-focused pipeline, and inducement grants are a common tool used by development-stage biotech firms competing for specialized scientific and operational talent.
Inducement equity awards are structured separately from a company's standard employee stock plan precisely to satisfy Nasdaq rules requiring that such grants serve as a material incentive for individuals to accept employment. The grants carry no immediate cash obligation for the company.
Continue reading at GlobeNewswire - Industry News on Financial Services.
